TA-65 and Aging Associated Microvascular Dysfunction

Launched by MEDICAL COLLEGE OF WISCONSIN · Oct 24, 2022

Keywords

ClinConnect Summary

This clinical trial is looking at a dietary supplement called TA-65 to see if it can help improve blood flow in small blood vessels, especially in people who may be affected by aging and certain vascular diseases. The aim is to understand if activating a specific enzyme called telomerase might have positive effects on microvascular function, which is important for overall health as we age.

To participate, you need to be a healthy adult between the ages of 18 and 35 or 65 and older. You also need to have a clinical diagnosis of coronary artery disease (CAD). However, some people won't be eligible, such as those aged 36 to 64 without CAD, those who exercise vigorously often, or anyone with certain medical conditions like heart failure or diabetes. If you join the trial, you’ll be helping researchers learn more about the potential benefits of TA-65, and you can expect to be monitored for your health throughout the study. If you have any questions or concerns about your eligibility or what participation involves, it’s important to discuss them with your healthcare provider.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Healthy Adults 18 - 35 and 65+ years of age
• • Subjects with clinical diagnosis of CAD
• Exclusion criteria will include:
• • 36-64 years of age without clinical diagnosis of CAD
• • Self-reported habitual vigorous exercise (\>20 min, 3 times per week, 1 yr)
• • Major Adverse Cardiovascular Event (MACE) in the last year (heart attack, stroke)
• • Heart Failure
• • Renal Impairment
• • \>3 Pre-existing Cardiovascular Risk Factors (healthy groups only)
• • Type 1 or type 2 diabetes
• • Uncontrolled hypertension
• • Current tobacco use or within last 6 months
• • BMI \> 35
• • Hyperlipidemia
• • Hypercholesterolemia
• • Use of anti-coagulant drugs
• • Use of anti-platelet drugs
• • Erectile dysfunction medication in the past 6 months
• • Use of topical/non-topical steroids in last 6 months
• • Hormone replacement therapy (Post-Menopause or Gender Reassignment)
• • History of retinopathy
• • Documented neuromuscular disorders
• • Porphyria Cutanea Tarda (blistering of skin to sun; photosensitivity)
• • Pregnancy (young female subjects)
• • Allergy to lidocaine
• • Current diagnosis of cancer with or without active anti-cancer treatment (pharmaceuticals) or treatment within last 12 months
• • Active COVID-19 or within the past 3 months